Literature DB >> 25876712

Decreased UBASH3A mRNA Expression Levels in Peripheral Blood Mononuclear Cells from Patients with Systemic Lupus Erythematosus.

Jie Liu1, Jing Ni, Lian-Ju Li, Rui-Xue Leng, Hai-Feng Pan, Dong-Qing Ye.   

Abstract

Increasing evidence has demonstrated the association between UBASH3A gene and multiple autoimmune diseases (ADs). The aim of our study was to explore the potential effect of UBASH3A messenger RNA (mRNA) expression and its role in the pathogenesis of systemic lupus erythematosus (SLE). UBASH3A mRNA levels were detected by real-time quantitative reverse transcription polymerase chain reaction (RT-qPCR) in total RNA, isolated from the peripheral blood mononuclear cells (PBMCs) of 32 SLE patients and 30 healthy donors with TRIzol Reagent. The expression level of UBASH3A mRNA was significantly reduced in PBMCs from SLE patients when compared with healthy controls (p = 0.002). UBASH3A mRNA expression levels in lower active SLE were significantly lower than that in inactive SLE groups (p = 0.000). There was a negative association between mRNA levels of hyper-active and lower-active SLE patients (p = 0.000). Moreover, a significant negative correlation between UBASH3A mRNA expression and the onset age of SLE patients was found (p = 0.044). A negative correlation was found between UBASH3A mRNA expression and SLEDAI (p = 0.049). Nevertheless, no significant difference was found between patients with lupus nephritis (LN) and those without LN (p = 0.392). The presence of leukopenia, positive for anti-dsDNA antibody and anti-SSB antibody were associated with UBASH3A mRNA levels in SLE patients (all p < 0.05). The dysregulation of UBASH3A mRNA levels in SLE patients and their correlations with experimental parameters suggested that UBASH3A may involve in the pathogenesis of SLE.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25876712     DOI: 10.1007/s10753-015-0170-9

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  33 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

Review 2.  TULA-family proteins: a new class of cellular regulators.

Authors:  Alexander Y Tsygankov
Journal:  J Cell Physiol       Date:  2013-01       Impact factor: 6.384

Review 3.  Multidomain STS/TULA proteins are novel cellular regulators.

Authors:  Alexander Y Tsygankov
Journal:  IUBMB Life       Date:  2008-04       Impact factor: 3.885

4.  Clinical relevance of plasma miR-21 in new-onset systemic lupus erythematosus patients.

Authors:  Zhao Ming Tang; Min Fang; Jin Ping Wang; Peng Cheng Cai; Ping Wang; Li Hua Hu
Journal:  J Clin Lab Anal       Date:  2014-03-22       Impact factor: 2.352

5.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.

Authors:  M C Hochberg
Journal:  Arthritis Rheum       Date:  1997-09

6.  Genome-wide association analysis of autoantibody positivity in type 1 diabetes cases.

Authors:  Vincent Plagnol; Joanna M M Howson; Deborah J Smyth; Neil Walker; Jason P Hafler; Chris Wallace; Helen Stevens; Laura Jackson; Matthew J Simmonds; Polly J Bingley; Stephen C Gough; John A Todd
Journal:  PLoS Genet       Date:  2011-08-04       Impact factor: 5.917

7.  Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX.

Authors:  Geoffrey Hom; Robert R Graham; Barmak Modrek; Kimberly E Taylor; Ward Ortmann; Sophie Garnier; Annette T Lee; Sharon A Chung; Ricardo C Ferreira; P V Krishna Pant; Dennis G Ballinger; Roman Kosoy; F Yesim Demirci; M Ilyas Kamboh; Amy H Kao; Chao Tian; Iva Gunnarsson; Anders A Bengtsson; Solbritt Rantapää-Dahlqvist; Michelle Petri; Susan Manzi; Michael F Seldin; Lars Rönnblom; Ann-Christine Syvänen; Lindsey A Criswell; Peter K Gregersen; Timothy W Behrens
Journal:  N Engl J Med       Date:  2008-01-20       Impact factor: 91.245

8.  Protein tyrosine phosphatase expression profile of rheumatoid arthritis fibroblast-like synoviocytes: a novel role of SH2 domain-containing phosphatase 2 as a modulator of invasion and survival.

Authors:  Stephanie M Stanford; Michael F Maestre; Amanda M Campbell; Beatrix Bartok; William B Kiosses; David L Boyle; Heather A Arnett; Tomas Mustelin; Gary S Firestein; Nunzio Bottini
Journal:  Arthritis Rheum       Date:  2013-05

9.  The Sts proteins target tyrosine phosphorylated, ubiquitinated proteins within TCR signaling pathways.

Authors:  Nick Carpino; Yunting Chen; Nicolas Nassar; Hye-Won Oh
Journal:  Mol Immunol       Date:  2009-09-05       Impact factor: 4.407

10.  Meta-analysis of genome-wide association studies in celiac disease and rheumatoid arthritis identifies fourteen non-HLA shared loci.

Authors:  Alexandra Zhernakova; Eli A Stahl; Gosia Trynka; Soumya Raychaudhuri; Eleanora A Festen; Lude Franke; Harm-Jan Westra; Rudolf S N Fehrmann; Fina A S Kurreeman; Brian Thomson; Namrata Gupta; Jihane Romanos; Ross McManus; Anthony W Ryan; Graham Turner; Elisabeth Brouwer; Marcel D Posthumus; Elaine F Remmers; Francesca Tucci; Rene Toes; Elvira Grandone; Maria Cristina Mazzilli; Anna Rybak; Bozena Cukrowska; Marieke J H Coenen; Timothy R D J Radstake; Piet L C M van Riel; Yonghong Li; Paul I W de Bakker; Peter K Gregersen; Jane Worthington; Katherine A Siminovitch; Lars Klareskog; Tom W J Huizinga; Cisca Wijmenga; Robert M Plenge
Journal:  PLoS Genet       Date:  2011-02-24       Impact factor: 5.917

View more
  2 in total

1.  β-Nicotinamide Mononucleotide (NMN) Administrated by Intraperitoneal Injection Mediates Protection Against UVB-Induced Skin Damage in Mice.

Authors:  Xianrong Zhou; Hang-Hang Du; Xingyao Long; Yanni Pan; Jian Hu; Jianjun Yu; Xin Zhao
Journal:  J Inflamm Res       Date:  2021-10-07

2.  Increased expression of hub gene CXCL10 in peripheral blood mononuclear cells of patients with systemic lupus erythematosus.

Authors:  Ruixian Zhang; Ya Li; Bangpin Pan; Yi Li; Aimin Liu; Xiaolan Li
Journal:  Exp Ther Med       Date:  2019-09-17       Impact factor: 2.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.